Treatment of Hot Flushes and Loss of Bone

A treatment is under developement for vasomotor symptoms and prevention of osteoporosis.

The combination should also prevent breast and uterine cancer.

Mechanism of Action

The combination of prasterone (DHEA), the cell-specific supplier of intracellular estrogens and androgens, with a highly specific blocker of estrogen action in the breast and uterus (acolbifene) has positive effects in bone where it slows down bone loss (acolbifene) while, simultaneously, (DHEA) stimulates bone formation.

Acolbifene, the estrogen receptor modulator (SERM) of Endoceutics has previously been used in several clinical studies performed in healthy postmenopausal women and in women with advanced breast cancer where positive results have been obtained. In women at high risk of breast cancer, phase II study performed by the US National Cancer Institute has shown a 77% decrease of the proliferation index in the mammary gland.

In addition, in preclinical studies, acolbifene decreased bone loss and had beneficial effects on lipids and fat accumulation.